Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07321834 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate AI-09 In Participants With Glabellar Lines
A Phase 2 study of Glabellar Lines, sponsored by Eirion Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 5
- Study locations
NCT07321834: Active Phase 2 study of Glabellar Lines, sponsored by Eirion Therapeutics.
NCT07321834 is a Phase 2 study of Glabellar Lines that is active but no longer recruiting, run by Eirion Therapeutics. The registered enrollment target is 68 participants, below the 397-participant average among 4 other Glabellar Lines trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07321834, a Phase 2 study of Glabellar Lines, is active but no longer recruiting, sponsored by Eirion Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 5
- Study locations
Study Summary
Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of AI-09, a Ready-to-Use Liquid Injectable Botulinum Toxin.
Primary Outcome
Change from Baseline (CfB) in IGA-C (Investigator Global Assessment on Contraction) as assessed using the 4-point Glabellar Line Severity Scale (GLS), with score "3" being Severe and score "0" being None.
Conditions Studied
Interventions
- BIOLOGICAL AI-09 Ready Use Injectable Botulinum Toxin
- BIOLOGICAL Vehicle
Study Locations (5)
Florida
- Center for Clinical and Cosmetic Research - Aventura
- Research Institute of the Southeast, Inc. - West Palm Beach
Louisiana
- Delricht Research - New Orleans
Tennessee
- Tennessee Clinical Research Center - Nashville
Texas
- Research Your Health - Plano
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2026-02 |
| Phase | Phase 2 |
What the registry record for NCT07321834 still lists
NCT07321834 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 397-participant average among 4 other Glabellar Lines trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Glabellar Lines appearing as the primary indexed condition, and to 2 interventions - of which AI-09 Ready Use Injectable Botulinum Toxin is the first listed.
NCT07321834 lists 5 locations in 4 states (Florida, Louisiana, Tennessee).
Frequently Asked Questions
What is clinical trial NCT07321834 about?
NCT07321834 is a clinical study titled "A Study to Evaluate AI-09 In Participants With Glabellar Lines". Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of AI-09, a Ready-to-Use Liquid Injectable Botulinum Toxin.
What is the current status of trial NCT07321834?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2025-12-03. Estimated completion is 2026-02.
What conditions does trial NCT07321834 study?
This clinical trial studies the following conditions: Glabellar Lines.
What interventions are being tested in trial NCT07321834?
The interventions under investigation include: AI-09 Ready Use Injectable Botulinum Toxin (BIOLOGICAL), Vehicle (BIOLOGICAL).
Who is sponsoring clinical trial NCT07321834?
This trial is sponsored by Eirion Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07321834 being conducted?
This trial has 5 study locations across Florida, Louisiana, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glabellar Lines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
COMPLETED · Phase 1
-
Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
COMPLETED · Phase 4
-
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
COMPLETED · Phase 3
-
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI